1. Home
  2. GKOS vs G Comparison

GKOS vs G Comparison

Compare GKOS & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.17

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Logo Genpact Limited

G

Genpact Limited

HOLD

Current Price

$38.83

Market Cap

7.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
G
Founded
1998
1997
Country
US
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
7.2B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
GKOS
G
Price
$116.17
$38.83
Analyst Decision
Strong Buy
Buy
Analyst Count
14
6
Target Price
$133.07
$49.50
AVG Volume (30 Days)
770.3K
2.6M
Earning Date
05-14-2026
01-01-0001
Dividend Yield
N/A
1.91%
EPS Growth
0.36
N/A
EPS
N/A
N/A
Revenue
$383,481,000.00
N/A
Revenue This Year
$23.29
$8.88
Revenue Next Year
$27.74
$7.47
P/E Ratio
N/A
$12.52
Revenue Growth
21.85
N/A
52 Week Low
$73.16
$34.79
52 Week High
$142.50
$55.00

Technical Indicators

Market Signals
Indicator
GKOS
G
Relative Strength Index (RSI) 52.32 38.85
Support Level $103.55 $36.50
Resistance Level $121.70 $41.00
Average True Range (ATR) 5.70 1.86
MACD -0.23 -0.08
Stochastic Oscillator 63.83 39.23

Price Performance

Historical Comparison
GKOS
G

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About G Genpact Limited

Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.

Share on Social Networks: